title: Immunomodulator effects on the Friend virus infection in genetically defined mice.
abstract: The disease induced by the Friend virus complex (FV) in F1 hybrid mice containing the Rfv-3r/s genotype in the presence of H-2a/a was used to evaluate a variety of immunomodulating substances. In these genetically defined mice, the FV disease results in splenomegaly, early production of high titers of cell-associated and plasma virus, high levels of splenic viral RNA, increased hematocrit, and eventual death. As the disease progresses, reduced levels of infectious virus correlate with development of specific antibody; reduction in T cell populations, increase in B cells, and decrease in T-cell function also occur. The following immunomodulators were evaluated, listed in the order of their ability to inhibit the FV disease: imexon > MVE-2 > human recombinant IFN-alpha A/D > AS101 > ampligen > AM-3 = oxamisole > ImuVert > bropirimine. In fact, bropirimine, used with certain treatment regimens, appeared to enhance the FV disease. These data suggest that certain immunomodulators may have potential value in the treatment of HIV disease, but also indicate that caution should be exercised in their clinical use.
authors.affiliation: Institute for Antiviral Research, Utah State University, Logan 84322-5600.
authors.forename: R W
authors.initials: RW
authors.lastname: Sidwell
authors.forename: J D
authors.initials: JD
authors.lastname: Morrey
authors.forename: K M
authors.initials: KM
authors.lastname: Okleberry
authors.forename: R A
authors.initials: RA
authors.lastname: Burger
authors.forename: R P
authors.initials: RP
authors.lastname: Warren
mesh_terms: D000276:Adjuvants, Immunologic / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use*; D003596:Cytosine / Q000031:analogs & derivatives / Q000627:therapeutic use; D005622:Friend murine leukemia virus / Q000187:drug effects*; D006588:Hexanones / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D007942:Leukemia, Experimental / Q000188:drug therapy* / Q000276:immunology; D008297:Male; D051379:Mice; D008805:Mice, Inbred A; D008815:Mice, Inbred Strains; D011070:Poly I-C / Q000627:therapeutic use; D011072:Poly U / Q000627:therapeutic use
chemical_list: D000276:Adjuvants, Immunologic; D000998:Antiviral Agents; D006588:Hexanones; D007166:Immunosuppressive Agents; D011072:Poly U; C014919:4-imino-1,3-diazabicyclo(3.1.0)hexan-2-one; D003596:Cytosine; C047490:poly(I).poly(c12,U); C033560:bropirimine; D011070:Poly I-C